AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21890585 — intervention group
Group type: COMPARATOR
Intervention: Alcohol (0.6 g/L)
Number of subjects: 9
Study 21890585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 19652099 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-lesson curriculum delivered during 28 hours by trained teachers
Number of subjects: 1722
Study 19652099 — intervention group
Group type: COMPARATOR
Intervention: Control schools targeted similar objectives without training or materials
Number of subjects: 1722
Study 17475735 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly interpersonal psychotherapy (IPT)
Number of subjects: 233
Study 17475735 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-monthly interpersonal psychotherapy (IPT)
Number of subjects: 233
Study 17475735 — intervention group
Group type: COMPARATOR
Intervention: Monthly interpersonal psychotherapy (IPT)
Number of subjects: 233
Study 17475735 — intervention group
Group type: EXPERIMENTAL
Intervention: IPT with selective serotonin reuptake inhibitor (SSRI)
Number of subjects: 233
Study 15025617 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg of bupivacaine and 50 microg of morphine
Number of subjects: 60
Study 15025617 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg of bupivacaine and 25 microg of fentanyl
Number of subjects: 60
Study 15025617 — intervention group
Group type: COMPARATOR
Intervention: 6 mg of bupivacaine and saline
Number of subjects: 60
Study 11283120 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan (1.5 mg/m²/day for 5 days every 21 days)
Number of subjects: 226
Study 11283120 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (175 mg/m² over 3 hours every 21 days)
Number of subjects: 226
Study 9258981 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg
Number of subjects: 15
Study 9258981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9258981 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloxacillin and Diclofenac
Number of subjects: 15
Study 7685226 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenidap sodium (40-120 mg/day)
Number of subjects: 0
Study 7685226 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (1000 mg/day)
Number of subjects: 0
Study 7685226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3808505 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt delivery (N = 26)
Number of subjects: 99
Study 3808505 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (N = 21)
Number of subjects: 99
Study 30614315 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhukovsky obstetric double balloon
Number of subjects: 41
Study 30614315 — intervention group
Group type: COMPARATOR
Intervention: Conventional hysterectomy
Number of subjects: 41
Study 29772695 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BoNT‐A) injections
Number of subjects: 16
Study 29772695 — intervention group
Group type: COMPARATOR
Intervention: Saline injections
Number of subjects: 16
Study 29772695 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT‐A injections
Number of subjects: 16
Study 26460205 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic mucosal microbiota
Number of subjects: 50
Study 26460205 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota
Number of subjects: 50
Study 26460205 — intervention group
Group type: EXPERIMENTAL
Intervention: Methane production
Number of subjects: 50
Study 26460205 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic transit
Number of subjects: 50
Study 26460205 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall composition of colonic mucosal microbiota
Number of subjects: 50
Study 25308064 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5mg estradiol cypionate (EC)
Number of subjects: 691
Study 25308064 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0mg estradiol cypionate (EC)
Number of subjects: 691
Study 25308064 — intervention group
Group type: COMPARATOR
Intervention: 1.0mg estradiol benzoate (EB)
Number of subjects: 691
Study 22398127 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg/d
Number of subjects: 72
Study 22398127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 20696552 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 434
Study 20696552 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine
Number of subjects: 434
Study 20696552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 434
Study 18410386 — intervention group
Group type: EXPERIMENTAL
Intervention: Emdogain
Number of subjects: 10
Study 18410386 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 10
Study 16112784 — intervention group
Group type: EXPERIMENTAL
Intervention: RBD patients with visual neglect
Number of subjects: 33
Study 16112784 — intervention group
Group type: COMPARATOR
Intervention: RBD patients without neglect
Number of subjects: 33
Study 16112784 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 33
Study 14671468 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 325
Study 14671468 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 40 mg/day
Number of subjects: 325
Study 11692340 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive amalgam restorations
Number of subjects: 0
Study 11692340 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonding of amalgam restorations
Number of subjects: 0
Study 7723447 — intervention group
Group type: EXPERIMENTAL
Intervention: Nottingham Health Profile (NHP)
Number of subjects: 0
Study 2254512 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Marital Therapy (BMT) Alone
Number of subjects: 60
Study 2254512 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Restructuring (CR) + BMT
Number of subjects: 60
Study 2254512 — intervention group
Group type: EXPERIMENTAL
Intervention: BMT + Emotional Expressiveness Training (EET)
Number of subjects: 60
Study 2254512 — intervention group
Group type: EXPERIMENTAL
Intervention: CR + BMT + EET
Number of subjects: 60
Study 2254512 — intervention group
Group type: COMPARATOR
Intervention: Waiting List
Number of subjects: 60
Study 6118980 — intervention group
Group type: EXPERIMENTAL
Intervention: Talinolol (cordanum) administered intravenously and then orally
Number of subjects: 9
Study 6118980 — intervention group
Group type: EXPERIMENTAL
Intervention: Talinolol (cordanum)
Number of subjects: 9
Study 6118980 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 11)
Number of subjects: 9
Study 31211381 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of FABP4
Number of subjects: 2194
Study 31211381 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of FABP4 in men
Number of subjects: 2194
Study 31211381 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of FABP4 in women
Number of subjects: 2194
Study 29802093 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based Driving in Dementia Decision Tool (DD-DT)
Number of subjects: 217
Study 29802093 — intervention group
Group type: COMPARATOR
Intervention: Control version of the tool (generic reminder about reporting legislation)
Number of subjects: 217
Study 29802093 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver concern
Number of subjects: 217
Study 29802093 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal clock drawing
Number of subjects: 217
Study 26253746 — intervention group
Group type: EXPERIMENTAL
Intervention: e-virtual reality exposure therapy (remote sessions)
Number of subjects: 6
Study 26253746 — intervention group
Group type: COMPARATOR
Intervention: traditional virtual reality exposure therapy (in-person sessions)
Number of subjects: 6
Study 24514431 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60
Study 24514431 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 60
Study 22652990 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal epidural injections of local anesthetic (lidocaine 0.5%)
Number of subjects: 100
Study 22652990 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal epidural injections with 0.5% lidocaine mixed with 1 mL of steroid (nonparticulate Celestone)
Number of subjects: 100
Study 22652990 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Group I and Group II)
Number of subjects: 100
Study 20012609 — intervention group
Group type: EXPERIMENTAL
Intervention: LVA (Left Ventricular-Assisted technique)
Number of subjects: 40
Study 20012609 — intervention group
Group type: COMPARATOR
Intervention: CPB (Conventional Cardiopulmonary Bypass)
Number of subjects: 40
Study 18587253 — intervention group
Group type: EXPERIMENTAL
Intervention: T1a tumor group
Number of subjects: 105
Study 18587253 — intervention group
Group type: EXPERIMENTAL
Intervention: T1b tumor group
Number of subjects: 105
Study 18587253 — intervention group
Group type: COMPARATOR
Intervention: Fascin-1 positivity
Number of subjects: 105
Study 18587253 — intervention group
Group type: COMPARATOR
Intervention: Extent of lamina propria invasion
Number of subjects: 105
Study 16135166 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil (8 mg)
Number of subjects: 24
Study 16135166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12350428 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast charge (fc: 1.0 Coulomb/s) stimulation
Number of subjects: 18
Study 12350428 — intervention group
Group type: COMPARATOR
Intervention: Slow charge (sc: 0.1 Coulomb/s) stimulation
Number of subjects: 18
Study 10028136 — intervention group
Group type: EXPERIMENTAL
Intervention: New model involving dependence between lead-time and post-lead-time survival
Number of subjects: 0
Study 10028136 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-parametric maximum likelihood estimator of post-lead-time survival
Number of subjects: 0
Study 10028136 — intervention group
Group type: COMPARATOR
Intervention: Screening
Number of subjects: 0
Study 7598235 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbonated lidocaine (20 mL of 1.73% carbonated lidocaine with epinephrine 5 micrograms/mL plus 2 mL of 0.9% NaCl, pH 6.42 +/- 0.04)
Number of subjects: 45
Study 7598235 — intervention group
Group type: EXPERIMENTAL
Intervention: pH adjusted lidocaine (20 mL of lidocaine with epinephrine 5 micrograms/mL plus 2 mL of 8.4% sodium bicarbonate, pH 6.47 +/- 0.16)
Number of subjects: 45
Study 7598235 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine HCl (control group, 20 mL of 2% lidocaine with epinephrine 5 micrograms/mL plus 2 mL of NaCl 0.9%, pH 4.58 +/- 0.10)
Number of subjects: 45
Study 7598235 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine HCl
Number of subjects: 45
Study 7598235 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbonated lidocaine
Number of subjects: 45
Study 2369808 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (0.5 mg)
Number of subjects: 17
Study 2369808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 2369808 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (locally infused)
Number of subjects: 17
Study 146524 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous physostigmine
Number of subjects: 25
Study 146524 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline chloride
Number of subjects: 25
Study 146524 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic treatment with oral choline chloride
Number of subjects: 25
Study 146524 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 5-g dose of choline chloride
Number of subjects: 25
Study 6127747 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine 75 mg
Number of subjects: 55
Study 6127747 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 3 mg
Number of subjects: 55
Study 6127747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 6127747 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 15 mg
Number of subjects: 55
Study 6127747 — intervention group
Group type: COMPARATOR
Intervention: Imipramine 50 mg
Number of subjects: 55
Study 31272408 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar anodal tDCS (20 min, 2 mA, ramp‐up and down periods of 30 s each, delivered over ten sessions)
Number of subjects: 20
Study 31272408 — intervention group
Group type: COMPARATOR
Intervention: Sham cerebellar tDCS
Number of subjects: 20
Study 29737796 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme 8371 USP unit of lipase, 3 times daily for 1 month
Number of subjects: 0
Study 29737796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26931347 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemented group received 400 IU of RRR‐α‐tocopheryl acetate.
Number of subjects: 89
Study 26931347 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation).
Number of subjects: 89
Study 26931347 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemented group.
Number of subjects: 89
Study 26931347 — intervention group
Group type: COMPARATOR
Intervention: Control group.
Number of subjects: 89
Study 24131304 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg lebrikizumab administered subcutaneously every 4 weeks over 12 weeks (total of four doses)
Number of subjects: 29
Study 24131304 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered subcutaneously every 4 weeks over 12 weeks (total of four doses)
Number of subjects: 29
Study 24131304 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg lebrikizumab
Number of subjects: 29
Study 22841233 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 80
Study 22841233 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 80
Study 22841233 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 20604695 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-centered peer-taught curriculum
Number of subjects: 599
Study 20604695 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual motivational interviewing intervention
Number of subjects: 599
Study 20604695 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 599
Study 18057361 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented fixation
Number of subjects: 501
Study 18057361 — intervention group
Group type: COMPARATOR
Intervention: Cementless fixation
Number of subjects: 501
Study 18057361 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented fixation (males)
Number of subjects: 501
Study 18057361 — intervention group
Group type: COMPARATOR
Intervention: Cementless fixation (males)
Number of subjects: 501
Study 15604157 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics at home
Number of subjects: 200
Study 15604157 — intervention group
Group type: COMPARATOR
Intervention: Intravenous antibiotics in hospital
Number of subjects: 200
Study 11862350 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 22
Study 11862350 — intervention group
Group type: EXPERIMENTAL
Intervention: Remacemide
Number of subjects: 22
Study 11862350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 10191283 — intervention group
Group type: EXPERIMENTAL
Intervention: Stanol ester margarine (2 or 3 g/day)
Number of subjects: 153
Study 8703669 — intervention group
Group type: EXPERIMENTAL
Intervention: theophylline + 200 mg nefazodone twice daily (every 12h)
Number of subjects: 13
Study 8703669 — intervention group
Group type: COMPARATOR
Intervention: theophylline + matching nefazodone placebo capsule twice daily (every 12h)
Number of subjects: 13
Study 8703669 — intervention group
Group type: EXPERIMENTAL
Intervention: theophylline + 200 mg nefazodone
Number of subjects: 13
Study 8703669 — intervention group
Group type: COMPARATOR
Intervention: theophylline + matching nefazodone placebo
Number of subjects: 13
Study 2203256 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic-effect (LGE) meal
Number of subjects: 6
Study 2203256 — intervention group
Group type: COMPARATOR
Intervention: High-glycemic-effect (HGE) meal
Number of subjects: 6
Study 457892 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolfing (Structural Integration)
Number of subjects: 48
Study 457892 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 29203209 — intervention group
Group type: EXPERIMENTAL
Intervention: BTHC-PCB
Number of subjects: 264
Study 29203209 — intervention group
Group type: COMPARATOR
Intervention: iopromide-PCB
Number of subjects: 264
Study 26329841 — intervention group
Group type: EXPERIMENTAL
Intervention: Below CRI
Number of subjects: 12
Study 26329841 — intervention group
Group type: COMPARATOR
Intervention: Above CRI
Number of subjects: 12
Study 25532515 — intervention group
Group type: EXPERIMENTAL
Intervention: rFSH + GnRH antagonist (n = 45)
Number of subjects: 108
Study 25532515 — intervention group
Group type: COMPARATOR
Intervention: rFSH (n = 63)
Number of subjects: 108
Study 23619901 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG-augmented diode laser therapy (ICG + DL) at a total dose of 4 mg/kg body weight
Number of subjects: 15
Study 23619901 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL) therapy before and after ICG administration (ICG + IPL)
Number of subjects: 15
Study 23619901 — intervention group
Group type: COMPARATOR
Intervention: Flashlamp-pumped pulsed dye laser (FPDL)
Number of subjects: 15
Study 19763572 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose HAIC (5-FU, 500 mg/m² on days 1-3 and cisplatin, 60 mg/m² on day 2)
Number of subjects: 68
Study 19763572 — intervention group
Group type: COMPARATOR
Intervention: Low-dose HAIC (5-FU, 170 mg/m² and cisplatin, 7 mg/m² on days 1-5)
Number of subjects: 68
Study 19763572 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose HAIC
Number of subjects: 68
Study 19763572 — intervention group
Group type: COMPARATOR
Intervention: Low-dose HAIC
Number of subjects: 68
Study 18447211 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-pricking therapy combined with spinal massage
Number of subjects: 93
Study 18447211 — intervention group
Group type: COMPARATOR
Intervention: Azulfidine (medication group)
Number of subjects: 93
Study 16392100 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral neck exploration
Number of subjects: 100
Study 16392100 — intervention group
Group type: COMPARATOR
Intervention: Bilateral neck exploration
Number of subjects: 100
Study 14738669 — intervention group
Group type: EXPERIMENTAL
Intervention: Endo-GIA Universal 6-row stapler (USSC)
Number of subjects: 100
Study 14738669 — intervention group
Group type: COMPARATOR
Intervention: ETS-Flex 6-row stapler (Ethicon)
Number of subjects: 100
Study 11192138 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (once daily, morning or evening)
Number of subjects: 1507
Study 9159299 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium ramping (linear from 155 mEq/L to 140 mEq/L)
Number of subjects: 23
Study 9159299 — intervention group
Group type: COMPARATOR
Intervention: Standard dialysis (steady dialysate sodium of 140 mEq/L)
Number of subjects: 23
Study 8439075 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized L‐Adrenaline and placebo (IM)
Number of subjects: 66
Study 8439075 — intervention group
Group type: COMPARATOR
Intervention: Nebulized saline and placebo (IM)
Number of subjects: 66
Study 8439075 — intervention group
Group type: COMPARATOR
Intervention: Nebulized saline and dexamethasone (IM)
Number of subjects: 66
Study 8439075 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized L‐Adrenaline and dexamethasone (IM)
Number of subjects: 66
Study 3530030 — intervention group
Group type: EXPERIMENTAL
Intervention: Birch pollen preparation (n = 14) with doses up to 1.4 X 10(6) biologic units per day
Number of subjects: 30
Study 3530030 — intervention group
Group type: EXPERIMENTAL
Intervention: Birch pollen preparation (n = 14)
Number of subjects: 30
Study 3530030 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 16)
Number of subjects: 30
Study 31854207 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (n=42)
Number of subjects: 81
Study 31854207 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=39)
Number of subjects: 81
Study 30552261 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective selective carious tissue removal
Number of subjects: 115
Study 30552261 — intervention group
Group type: COMPARATOR
Intervention: Objective selective removal with a self-limiting bur (Polybur, Komet)
Number of subjects: 115
Study 27255560 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.5% plus 8 mg dexamethasone
Number of subjects: 200
Study 27255560 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine 0.5%
Number of subjects: 200
Study 26597415 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP‐based lifestyle intervention
Number of subjects: 92
Study 26597415 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 92
Study 26597415 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 92
Study 23919573 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Nurse Partnership programme
Number of subjects: 1600
Study 23919573 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1600
Study 20429838 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteomic profiling using off‐line strong cation exchange fractionation with RP‐LC‐ESI‐MS/MS
Number of subjects: 54
Study 20429838 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteomic profiling
Number of subjects: 54
Study 18761784 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg continuously once daily
Number of subjects: 62
Study 18761784 — intervention group
Group type: COMPARATOR
Intervention: Levocetirizine 5 mg on-demand
Number of subjects: 62
Study 15893525 — intervention group
Group type: EXPERIMENTAL
Intervention: Similarity judgments, short‐term memory and long‐term learning tasks among semi‐nomadic tribesmen
Number of subjects: 0
Study 15893525 — intervention group
Group type: EXPERIMENTAL
Intervention: Categorical Perception effects
Number of subjects: 0
Study 13678869 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (target dose 32 mg once daily)
Number of subjects: 2548
Study 13678869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2548
Study 13678869 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 2548